Endomag

Executive Summary

Endomag is a UK-based medical technology company specializing in radiation-free magnetic tracers for breast cancer staging. Its lead product, Magtrace, is a magnetic lymphatic tracer used in sentinel lymph node biopsy (SLNB), offering a safe, flexible alternative to radioactive tracers and blue dyes. Approved in the EU and UK, Magtrace addresses the logistical burdens and safety concerns of traditional methods, particularly in settings where nuclear medicine facilities are limited. The company is expanding its clinical evidence base to support broader adoption and potential FDA clearance in the US, a key market for growth. The global breast cancer diagnostics market is sizable, with increasing emphasis on minimally invasive, patient-friendly techniques. Endomag's technology has the potential to become the standard of care in SLNB, especially as hospitals seek to eliminate radioactive waste and improve workflow. The company has secured partnerships with leading cancer centers and continues to generate positive clinical data. With a strong IP portfolio and growing commercial traction, Endomag is well-positioned for further market penetration and potential acquisition interest from larger medical device firms.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for Magtrace in the US market60% success
• Q2 2026Publication of pivotal trial results for Magtrace in breast cancer patients80% success
• TBDStrategic partnership or distribution agreement for expansion into additional cancer indications (e.g., melanoma)50% success